← Back to Search

Anti-metabolites

Sequential ascending dose cohort for Epilepsy

Phase 2
Waitlist Available
Led By Nathan B Fountain, MD
Research Sponsored by University of Virginia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from time of drug administration until 24 hours post-dose
Awards & highlights

Study Summary

This trial studies how 2DG pills are absorbed and distributed in patients with epilepsy to see if they can stop seizures.

Eligible Conditions
  • Epilepsy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from time of drug administration until 24 hours post-dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and from time of drug administration until 24 hours post-dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Treatment-Emergent Adverse Events
Pharmacokinetics

Side effects data

From 2011 Phase 2 trial • 55 Patients • NCT00062374
65%
Fatigue
64%
Hypocalcemia
60%
Nausea
58%
White blood cell count decrease
56%
Neutrophil count decrease
55%
Hemoglobin decrease
45%
Diarrhea
38%
Platelet count decreased
36%
Hyponatremia
31%
Hypophosphatemia
29%
Anorexia
29%
Hypokalemia
27%
Abdominal pain/cramping
22%
Hypomagnesemia
22%
Vomiting
20%
Hyperglycemia
20%
Hyperkalemia
20%
Lymphocyte count decrease
20%
Neuropathy-sensory
20%
Hypoalbuminemia
18%
Alanine aminotransferase increase
13%
Dyspnea
13%
Aspartate aminotransferase increase
11%
Creatinine
11%
Dehydration
11%
Dizziness
11%
Edema
9%
Thrombosis
9%
Alopecia
9%
Hypernatremia
9%
Weight loss
7%
Hearing impaired
7%
Constipation
7%
Dyspepsia
7%
Mood alteration/anxiety
7%
Taste disturbance
5%
Febrile neutropenia
5%
Dysphagia
5%
Pain, other
5%
Hypoglycemia
5%
Pharyngeal mucositis
4%
Hemorrhage, NOS
4%
CNS/cerebrovascular ischemia
4%
Chest pain
2%
Gastrointestinal disorder
2%
Cardiovascular, other
2%
Seizure
2%
Hypotension
2%
Muscle weakness
2%
Creatinine increased
100%
80%
60%
40%
20%
0%
Study treatment Arm
Arm I

Trial Design

1Treatment groups
Experimental Treatment
Group I: Sequential ascending dose cohortExperimental Treatment1 Intervention
Cohort 1 will receive single 40 mg dose once. Cohort 2 will receive single 60 mg dose once. Cohort 3 will receive (2) 60 mg dose on one occasion.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Oral 2-Deoxy-D-Glucose (2DG)
2022
Completed Phase 2
~10

Find a Location

Who is running the clinical trial?

Epilepsy FoundationOTHER
10 Previous Clinical Trials
406 Total Patients Enrolled
8 Trials studying Epilepsy
363 Patients Enrolled for Epilepsy
University of VirginiaLead Sponsor
759 Previous Clinical Trials
1,245,577 Total Patients Enrolled
1 Trials studying Epilepsy
294 Patients Enrolled for Epilepsy
University of Wisconsin, MadisonOTHER
1,193 Previous Clinical Trials
3,161,830 Total Patients Enrolled
5 Trials studying Epilepsy
161 Patients Enrolled for Epilepsy

Media Library

2-Deoxy-D-Glucose (2DG) (Anti-metabolites) Clinical Trial Eligibility Overview. Trial Name: NCT05605301 — Phase 2
Epilepsy Research Study Groups: Sequential ascending dose cohort
Epilepsy Clinical Trial 2023: 2-Deoxy-D-Glucose (2DG) Highlights & Side Effects. Trial Name: NCT05605301 — Phase 2
2-Deoxy-D-Glucose (2DG) (Anti-metabolites) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05605301 — Phase 2
~3 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top